首页> 外文期刊>Marine Drugs >Identification of Antiviral Agents Targeting Hepatitis B Virus Promoter from Extracts of Indonesian Marine Organisms by a Novel Cell-Based Screening Assay
【24h】

Identification of Antiviral Agents Targeting Hepatitis B Virus Promoter from Extracts of Indonesian Marine Organisms by a Novel Cell-Based Screening Assay

机译:新型基于细胞的筛选方法从印尼海洋生物提取物中鉴定靶向乙肝病毒启动子的抗病毒药物

获取原文
       

摘要

The current treatments of chronic hepatitis B (CHB) face a limited choice of vaccine, antibody and antiviral agents. The development of additional antiviral agents is still needed for improvement of CHB therapy. In this study, we established a screening system in order to identify compounds inhibiting the core promoter activity of hepatitis B virus (HBV). We prepared 80 extracts of marine organisms from the coral reefs of Indonesia and screened them by using this system. Eventually, two extracts showed high inhibitory activity (95%) and low cytotoxicity (66% to 77%). Solvent fractionation, column chromatography and NMR analysis revealed that 3,5-dibromo-2-(2,4-dibromophenoxy)-phenol (compound 1) and 3,4,5-tribromo-2-(2,4-dibromophenoxy)-phenol (compound 2), which are classified as polybrominated diphenyl ethers (PBDEs), were identified as anti-HBV agents in the extracts. Compounds 1 and 2 inhibited HBV core promoter activity as well as HBV production from HepG2.2.15.7 cells in a dose-dependent manner. The EC50 values of compounds 1 and 2 were 0.23 and 0.80 μM, respectively, while selectivity indexes of compound 1 and 2 were 18.2 and 12.8, respectively. These results suggest that our cell-based HBV core promoter assay system is useful to determine anti-HBV compounds, and that two PBDE compounds are expected to be candidates of lead compounds for the development of anti-HBV drugs.
机译:慢性乙型肝炎(CHB)的当前治疗面临疫苗,抗体和抗病毒剂的有限选择。仍需要开发其他抗病毒药物来改善CHB治疗。在这项研究中,我们建立了筛选系统,以鉴定抑制乙型肝炎病毒(HBV)核心启动子活性的化合物。我们从印度尼西亚的珊瑚礁中提取了80种海洋生物提取物,并使用此系统进行了筛选。最终,两种提取物表现出高抑制活性(> 95%)和低细胞毒性(66%至77%)。溶剂分馏,柱色谱和NMR分析表明3,5-二溴-2-(2,4-二溴苯氧基)-苯酚(化合物1)和3,4,5-三溴-2-(2,4-二溴苯氧基)-在提取物中,苯酚(化合物2)被归类为多溴联苯醚(PBDEs),被确定为抗乙肝病毒药物。化合物1和2以剂量依赖性方式抑制HBV核心启动子活性以及从HepG2.2.15.7细胞产生HBV。化合物1和2的EC <50>值分别为0.23和0.80μM,而化合物1和2的选择性指数分别为18.2和12.8。这些结果表明,我们基于细胞的HBV核心启动子测定系统可用于确定抗HBV化合物,并且两种PBDE化合物有望成为开发抗HBV药物的先导化合物的候选者。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号